Medicaid Drug Rebates Will Get Closer Scrutiny From CMS, Verma Pledges
Executive Summary
CMS Administrator-nominee Seema Verma promises stronger agency oversight of Medicaid drug rebate program in response to question from Sen. Grassley during Senate confirmation hearing.
You may also be interested in...
EpiPen Pricing Got Mylan In Hot Water; Now Sanofi Is Taking Firm To Court
Sanofi claims Mylan blocked its competing Auvi-Q product from the market by offering rebates to payers on the condition they would only reimburse for EpiPen; Sanofi seeks treble damages for lost sales.
US Medicaid Reform: Legislators Caution CMS Nominee About Coverage Loss
Seema Verma is closely identified with Medicaid reform but both Republicans and Democrats expressed concern during her Senate confirmation hearing that reforms not translate into loss of insurance coverage.
Medicaid Discount Classification: Will Trump And Grassley Tag Team Against Pharma?
Confirmation hearing for HHS Nominee Price could give Sen. Grassley chance to get new administration on record prioritizing enforcement against drugs that have been providing smaller than appropriate Medicaid discounts.